Studies show that based on anti-PD1/PD-L1 treatment combined with other therapies, such as radiotherapy, chemotherapy, targeted therapy, and other therapies, lung cancer treatment can be optimized and adverse events can be reduced [21]. This evidence concerns the gene CD274 and lung carcinoma.